Phil Shawe is the Co-Founder and Co-CEO of TransPerfect, a global family of companies and the world’s largest privately held provider of language and business services. Phil has overseen the day-to-day operations of the company for over 25 years, and grown the business from two people to an industry leader with over 4,000 employees and 100 offices worldwide.
Under Phil’s leadership, TransPerfect has received numerous awards and distinctions. The company is a seven-time honoree of the Inc. 5000 Award, a six-time honoree of the Deloitte Technology Fast 500, and has earned multiple Stevie Awards for Sales and Customer Service. Phil has been named Entrepreneur of the Year for New York City by Ernst & Young, and named to Crain’s New York prestigious “40 Under 40 list” as one of the top young executives in New York. Crain’s has also ranked TransPerfect as one of the largest privately held companies nine years in a row. TransPerfect was also named to fastest-growing lists six times by Entrepreneur.
Phil has guest lectured on Entrepreneurship at New York University and Columbia University, and is a member of the Association for a Better New York (ABNY). Previously, Phil was a member of the board of directors of The Joyful Heart Foundation, a non-profit that worked in support of survivors of sexual assault, domestic violence, and child abuse. His philanthropic efforts include supporting over 25 causes by donating time or financial support, and he was recently named to The V Foundation for Cancer Research’s Circle of Honor.
Having success in #diversity is a journey, not a destination. Our different backgrounds and cultures define @TransPerfect and make us successful. That is why we dedicated an entire month to focus on celebrating diversity, featuring speeches from global thought leaders. https://t.co/U54TF6vX0i
Introducing our first #AI-powered TMF automation is a great step forward for Trial Interactive clients. The faster document processing is for study teams, the faster sponsors can bring treatments to patients. #eTMF #clinicaltrials
Full Release: https://t.co/tWKGrkTESp